| Dr Ghadeer Okayli, MD PSYCHIATRIST | |
|
709 Meriden Ln, Austin, TX 78703-4523 | |
| (512) 632-6003 | |
| (512) 519-2996 |
| Full Name | Dr Ghadeer Okayli |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 709 Meriden Ln, Austin, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194831032 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | L7831 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ghadeer Okayli, MD PSYCHIATRIST 709 Meriden Ln, Austin, TX 78703-4523 Ph: (512) 632-6003 | Dr Ghadeer Okayli, MD PSYCHIATRIST 709 Meriden Ln, Austin, TX 78703-4523 Ph: (512) 632-6003 |
News Archive
Covidien, a leading global provider of healthcare products, recently brought together six of the world's prominent thought-leaders in stroke at the 2013 European Stroke Conference.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
Oral cancer is the 8th most common cancer in men and ranks 14th among women worldwide. There were 274,300 new cases and 145,500 deaths worldwide in 2002. Two-thirds of this burden are borne by developing countries, and over 30% by India alone. A high rate of oral cancer has been recorded in the Indian subcontinent, central and eastern Europe, parts of France, southern Europe, South America, and Oceania.
The U.S. Food and Drug Administration should gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices, says a new report from the Institute of Medicine.
› Verified 1 days ago
Dr. Chad Alan Hooten, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 601 E 15th St, Austin, TX 78701 Phone: 512-324-2000 | |
Kristin Yeung Lasseter, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 4022 Menchaca Rd, Austin, TX 78704 Phone: 512-982-4116 Fax: 512-265-9008 | |
Priyanka Gurru, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1201 W 38th St, Austin, TX 78705 Phone: 512-495-5555 | |
Kira Allison, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1500 Red River St, Austin, TX 78701 Phone: 512-495-5555 | |
Robert Feinstein, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1601 Trinity St, Austin, TX 78712 Phone: 833-882-2737 Fax: 888-698-8329 | |
Ava M. Lee, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 56 East Ave, Austin, TX 78701 Phone: 512-472-4357 Fax: 512-703-1394 | |
Dr. Lindsay Erin Elton, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 7940 Shoal Creek Blvd Ste 100, Austin, TX 78757 Phone: 512-494-4000 Fax: 512-494-4024 |